Business Description
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.39 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.82 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | -45.1 | |||||
3-Year EPS without NRI Growth Rate | -17.3 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
3-Year Book Growth Rate | -42.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 27.05 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.64 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.11 | |||||
9-Day RSI | 62.38 | |||||
14-Day RSI | 63.98 | |||||
6-1 Month Momentum % | 3.17 | |||||
12-1 Month Momentum % | 20.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.54 | |||||
Quick Ratio | 3.39 | |||||
Cash Ratio | 2.8 | |||||
Days Inventory | 200.73 | |||||
Days Sales Outstanding | 65.13 | |||||
Days Payable | 257.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.2 | |||||
Shareholder Yield % | -0.23 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.15 | |||||
Operating Margin % | -114.04 | |||||
Net Margin % | -121.57 | |||||
FCF Margin % | -102.29 | |||||
ROE % | -290 | |||||
ROA % | -42 | |||||
ROIC % | -75.33 | |||||
3-Year ROIIC % | -87.7 | |||||
ROC (Joel Greenblatt) % | -175.01 | |||||
ROCE % | -45.87 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.5 | |||||
PB Ratio | 12 | |||||
Price-to-Tangible-Book | 23.83 | |||||
EV-to-EBIT | -8.86 | |||||
EV-to-Forward-EBIT | -6.66 | |||||
EV-to-EBITDA | -9.47 | |||||
EV-to-Forward-EBITDA | -6.73 | |||||
EV-to-Revenue | 9.58 | |||||
EV-to-Forward-Revenue | 6.82 | |||||
EV-to-FCF | -9.06 | |||||
Earnings Yield (Greenblatt) % | -11.29 | |||||
FCF Yield % | -9.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 445.406 | ||
EPS (TTM) (€) | -6.764 | ||
Beta | 0.73 | ||
Volatility % | 45.25 | ||
14-Day RSI | 63.98 | ||
14-Day ATR (€) | 0.660864 | ||
20-Day SMA (€) | 50.12 | ||
12-1 Month Momentum % | 20.63 | ||
52-Week Range (€) | 30 - 52 | ||
Shares Outstanding (Mil) | 92.17 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ultragenyx Pharmaceutical Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(FRA:UP0)'s stock price today?
When is next earnings date of Ultragenyx Pharmaceutical Inc(FRA:UP0)?
Does Ultragenyx Pharmaceutical Inc(FRA:UP0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |